Claims

1. Use of a ligand of a cellular marker selected from the group comprising CDw52, Claudin 7, Ephrin A1, AMFR, MME, FGFR3 for the preparation of a medicament for the treatment of solid tumours expressing at least one of said cellular markers.

2. Use according to claim 1, wherein the cellular marker expressing solid tumours are selected from the group of bone tumours, in particular slowly proliferating bone tumours.

3. Use according to claim 1 or 2, wherein the cellular marker expressing solid tumours are selected from the group of giant cell tumours, chondrosarcomas, and osteosarcomas.

4. Use according to any of claims 1 to 3, wherein the ligand is selected from a cellular marker-specific antibody, a fragment thereof, a cellular marker-binding peptide, and a cellular marker-interacting substance.

5. Use according to claim 4, wherein the ligand is alemtuzumab (Campath-1H).

6. Use according to any of claims 1 to 5, wherein the ligand is administered systemically and/or administered locally.

7. Use according to any of claims 1 to 6, wherein the ligand is present in the medicament in concentrations that provide in vivo concentrations of said ligand in a patient to be treated of between 0.01 mg/kg/day and 1 mg/kg/day.

8. Use according to any of claims 1 to 7, wherein the ligand is for administration in combination with other chemotherapeutically active substances.

9. Use according to any of claims 1 to 8, wherein the ligand is for a specific treatment of mGCs, macrophage-like cells, and fibroblast-like cells of the tumour.

10. Use of a cellular marker selected from the group comprising CDw52, Claudin 7, Ephrin A1, AMFR, MME, FGFR3 for the diagnosis of solid tumours expressing at least one of said cellular markers.

11. Use according to claim 11, wherein the cellular marker expressing solid tumours are selected from the group of bone tumours, in particular slowly proliferating bone tumours.

12. Use according to claim 10 or 11, wherein the cellular marker expressing solid tumours are selected from the group of giant cell tumours, chondrosarcomas, and osteosarcomas.

13. Use according to any of claims 10 to 12, wherein the diagnosis comprises the distinction between mGCs, macrophage-like cells, and fibroblast-like cells of the tumour.

14. An improved method for screening for ligands of a cellular marker selected from the group comprising CDw52, Claudin 7, Ephrin A1, AMFR, MME, FGFR3, comprising the steps of:

a) incubating a cell expressing at least one marker selected from CDw52, Claudin 7, Ephrin A1, AMFR, MME, and FGFR3 with a putative ligand,

b) measuring, if a binding between at least one marker selected from CDw52, Claudin 7, Ephrin A1, AMFR, MME, and FGFR3 and said putative ligand occurs, and

c) in the case of a binding of said ligand to at least one marker is measured, measuring, if said binding between said at least one marker and said identified ligand also leads to a marker-mediated death of a marker-expressing solid tumour cell.

15. Method for the production of a pharmaceutical formulation, comprising the steps of:

a) performing a method according to claim 14, and

b) formulating the identified ligand for said at least one marker with pharmaceutically acceptable carriers and/or excipients.